Cargando…
NSC23925, Identified in a High-Throughput Cell-Based Screen, Reverses Multidrug Resistance
BACKGROUND: Multidrug resistance (MDR) is a major factor which contributes to the failure of cancer chemotherapy, and numerous efforts have been attempted to overcome MDR. To date, none of these attempts have yielded a tolerable and effective therapy to reverse MDR; thus, identification of new agent...
Autores principales: | Duan, Zhenfeng, Choy, Edwin, Hornicek, Francis J. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2757897/ https://www.ncbi.nlm.nih.gov/pubmed/19823672 http://dx.doi.org/10.1371/journal.pone.0007415 |
Ejemplares similares
-
Prevention of multidrug resistance (MDR) in osteosarcoma by NSC23925
por: Yang, X, et al.
Publicado: (2014) -
Pharmacokinetics and tolerability of NSC23925b, a novel P-glycoprotein inhibitor: preclinical study in mice and rats
por: Gao, Yan, et al.
Publicado: (2016) -
Novel Quinoline Compound Derivatives of NSC23925 as Potent Reversal Agents Against P-Glycoprotein-Mediated Multidrug Resistance
por: Quan, Xingping, et al.
Publicado: (2019) -
Oleanane triterpenoid CDDO-Me induces apoptosis in multidrug resistant osteosarcoma cells through inhibition of Stat3 pathway
por: Ryu, Keinosuke, et al.
Publicado: (2010) -
miR‐15b modulates multidrug resistance in human osteosarcoma in vitro and in vivo
por: Duan, Zhenfeng, et al.
Publicado: (2016)